Pressmeddelanden
Coegin Pharma reports positive NPP-4 safety results - advancing a potential breakthrough in sunless tanning
Coegin Pharma AB ("Coegin" or the "Company") today announces positive results from its comprehensive NPP-4 safety program, including preclinical safety evaluations and clinical c...
REG
Coegin Pharma Calls SEK 6 Million Under Previously Announced Capital Facility
The Board of Directors of Coegin Pharma AB (publ) ("the Company" or "Coegin Pharma") has today resolved to call SEK 6 million under the capital facility of SEK 16 million announc...
Coegin Pharma reports strong clinical results for Follicopeptide® in eyelashes - statistically significant increase in eyelash length confirmed
Coegin Pharma AB ("Coegin" or the "Company") today announces encouraging results from a completed 56-day clinical study evaluating Follicopeptide® Lash Gel Serum for eyelashes. V...
REG
MAR
Coegin Pharma AB publishes its interim report for the second quarter of 2026
Summary of interim reportThe second quarter of 2026 represents another important step in Coegin Pharma's transformation. Less than a year ago the Company was preparing its first...
Coegin Pharma provides an update on product development and upcoming product launches
Coegin Pharma AB ("Coegin" or the "Company") today provides an update on the expansion of its Follicopeptide®-based product portfolio. Development is progressing across several n...
REG
Communiqué from the Extraordinary General Meeting of Coegin Pharma AB (publ)
Today, on July 22, 2026, the Extraordinary General Meeting of Coegin Pharma AB (publ) ("Coegin Pharma" or the "Company") was held. A summary of the resolution passed by the Extra...
Rapporter
Video
Finansiell kalender
Om Coegin Pharma
Coegin Pharma är ett svenskt innovationsbolag som utvecklar och kommersialiserar avancerade kosmetiska teknologier för hår och hud.
Webbplats
www.coeginpharma.com
Bransch
Bioteknik
Prenumerera
Få löpande information från Coegin Pharma via e-post.
Handelsinformation
Kurs 2,21 SEK (2026-10-19)
Förändring −69,48% (2025-10-17)